Grifols Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Los beneficios de Grifols han disminuido a una tasa media anual de -38.9%, mientras que en la industria Biotechs los beneficios crecieron en un 17.7% anualmente. Los ingresos han ido creciendo a una tasa media de 6.4% al año. La rentabilidad financiera de Grifols es de 2.3%, y sus márgenes netos son de 0.9%.

Información clave

-38.9%

Tasa de crecimiento de los beneficios

-30.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	11.5%
Tasa de crecimiento de los ingresos	6.4%
Rentabilidad financiera	2.3%
Margen neto	0.9%
Próxima actualización de resultados	14 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Grifols. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

LSE:0RDU Ingresos, gastos y beneficios (EUR Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	6,592	59	1,367	395
30 Sep 23	6,535	23	1,343	388
30 Jun 23	6,479	8	1,336	393
31 Mar 23	6,358	47	1,345	390
31 Dec 22	6,064	208	1,190	361
30 Sep 22	5,549	149	1,138	353
30 Jun 22	5,207	66	1,122	358
31 Mar 22	5,016	112	1,064	359
31 Dec 21	4,933	189	1,062	355
30 Sep 21	5,044	361	1,046	337
30 Jun 21	5,199	667	1,008	311
31 Mar 21	5,231	562	992	298
31 Dec 20	5,340	619	986	294
30 Sep 20	5,392	687	971	288
30 Jun 20	5,353	557	976	286
31 Mar 20	5,235	697	959	281
31 Dec 19	5,099	625	943	276
30 Sep 19	4,961	552	923	271
30 Jun 19	4,790	565	878	261
31 Mar 19	4,620	568	859	249
31 Dec 18	4,487	597	815	241
30 Sep 18	4,332	699	777	212
30 Jun 18	4,246	704	804	215
31 Mar 18	4,279	672	800	219
31 Dec 17	4,318	663	860	225
30 Sep 17	4,348	571	857	230
30 Jun 17	4,291	559	827	222
31 Mar 17	4,153	554	810	209
31 Dec 16	4,050	545	775	198
30 Sep 16	4,014	537	771	216
30 Jun 16	3,986	535	776	218
31 Mar 16	3,985	529	768	221
31 Dec 15	3,935	532	736	224
30 Sep 15	3,789	533	696	211
30 Jun 15	3,645	507	686	199
31 Mar 15	3,466	478	666	194
31 Dec 14	3,355	470	661	181
30 Sep 14	3,133	417	647	161
30 Jun 14	2,972	388	614	150
31 Mar 14	2,856	376	584	132
31 Dec 13	2,742	346	558	123
30 Sep 13	2,708	326	558	124
30 Jun 13	2,685	306	551	124

Ingresos de calidad: 0RDU tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(0.9%) de 0RDU son inferiores a los del año pasado (3.4%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de 0RDU han disminuido en un 38.9% al año en los últimos 5 años.

Acelerando crecimiento: 0RDU ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: 0RDU tuvo un crecimiento negativo de los beneficios (-71.5%) durante el año pasado, lo que dificulta la comparación con la media de la industria Biotechs (-8.7%).

Grifols Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Información clave

Actualizaciones de resultados anteriores recientes

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Full year 2023 earnings released

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Third quarter 2023 earnings released

Second quarter 2023 earnings released

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Recent updates

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Now 20% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 41%

Full year 2023 earnings released

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Third quarter 2023 earnings released

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

New major risk - Financial position

Second quarter 2023 earnings released

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

New major risk - Financial position

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Launches Alphaid™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic Copd

Investor sentiment improves as stock rises 19%

Investor sentiment deteriorates as stock falls 15%

Full year 2022 earnings released

Now 20% undervalued

Grifols, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023

Now 22% undervalued

Now 22% undervalued after recent price drop

Insufficient new directors

Grifols, S.A. to Report Q3, 2022 Results on Nov 08, 2022

Grifols Receives FDA Clearance for AlphaID(TM) At Home, the First Free Service for U.S. Consumers to Determine Their Risk for Alpha-1

Insufficient new directors

Grifols Announces Management Changes

Second quarter 2022 earnings released

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Now 20% undervalued after recent price drop

Now 20% undervalued

Grifols, S.A. to Report First Half, 2022 Results on Jul 28, 2022

Now 20% undervalued

Now 23% undervalued

Grifols, S.A., Annual General Meeting, Jun 09, 2022

Insufficient new directors

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.

Full year 2021 earnings: Revenues miss analyst expectations

Grifols, S.A. (BME:GRF) acquired Grifols Escrow Issuer, S.A.U. for $0.06 million.

Investor sentiment improved over the past week

Now 22% undervalued after recent price drop

Second quarter 2021 earnings released

Independent External Director Ramon Riera Roca has left the company

Grifols to Provide Korean Red Cross with Procleix Panther for Blood Screening, Extending Donor Testing Leadership in Asia

Grifols, S.A. Declares Ordinary Dividend for the Fiscal Year Ended December 31, 2020, Payable on June 7, 2021

Grifols Takes Another Step in the Fight Against Alzheimer's, Partners with Ace to Open First Ambar® Center in Barcelona

First quarter 2021 earnings released: EPS €0.19 (vs €0.27 in 1Q 2020)

Full year 2020 earnings released: EPS €0.90 (vs €0.91 in FY 2019)

Grifols Launches Patient Point-Of-Care System for Monitoring Infliximab in Europe

Grifols, S.A. (BME:GRF) acquired remaining 56% stake in GigaGen, Inc. for $80 million

Grifols, S.A. (BME:GRF) acquired 25 U.S. Based Plasma Donation Centers of BPL Plasma, Inc for $370 million.

Full year 2020 earnings released: EPS €0.90 (vs €0.91 in FY 2019)

Revenue misses expectations

New 90-day low: €20.77

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Desglose de ingresos y gastos
Beta